DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
05/24/2019 - 10:30 pm
DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of DirectorsDownload PDF (137 KB)
05/14/2019 - 7:30 am
DBV Technologies Announces Departure of Deputy CEO David SchilanskyDownload PDF (163 KB)
05/03/2019 - 10:30 pm | General Assembly
Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General MeetingDownload PDF (156 KB)